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Abstract
Background: In the randomized study of interferon beta-1b (IFN beta-1b) for multiple sclerosis (MS), it has usually
been evaluated the simple annual relapse rate as the study endpoint. This study aimed to investigate the
performance of various regression models using information regarding the time to each recurrent event and
considering the MS specific data generation process, and to estimate the treatment effect of a MS clinical trial data.
Methods: We conducted a simulation study with consideration of the pathological characteristics of MS, and
applied alternative efficacy estimation methods to real clinical trial data, including 5 extended Cox regression
models for time-to-event analysis, a Poisson regression model and a Poisson regression model with Generalized
Estimating Equations (GEE). We adjusted for other important covariates that may have affected the outcome.
Results: We compared the simulation results for each model. The hazard ratios of real data were estimated for
each model including the effects of other covariates. The results (hazard ratios of high-dose to low-dose) of all
models were approximately 0.7 (range, 0.613 - 0.769), whereas the annual relapse rate ratio was 0.714.
Conclusions: The precision of the treatment estimation was increased by application of the alternative models.
This suggests that the use of alternative models that include recurrence event data may provide better analyses.
Background
Multiple sclerosis (MS) is the most common demyeli-
nating disorder of the central nervous system, and is
characterized by repeated episodes of neurological dys-
function with variable remission. Since 1993, the benefi-
cial effects of interferon beta have been shown [1], and
in Japan, interferon beta-1b (IFN beta-1b) has signifi-
cantly reduced relapse rates and reduced MRI lesion
areas in patients with relapsing-remitting MS [2].
Recently, Kappos et al. [3] reported that IFN beta-1b
can delay the conversion to clinically definite MS. Car-
roll [4] performed a comprehensive review of clinical
studies of MS therapies.
The long-term treatment effects for chronic recurrent
diseases such as MS should be evaluated in clinical
trials. In the past, the primary endpoint in clinical trials
of MS has been the annual relapse rate, the change in a
clinical indicator such as the Expanded Disability Status
Scale (EDSS) score or total area of MS lesions on the
MRI scan from entry time, the proportion of non-
relapsed patients, or the time to the first recurrence
[1,2,5-10]. Meanwhile, extended methods of survival
analysis for time-to-event data have been proposed, and
such methods are useful when study subjects experience
2 or more events. Considering the recurrent events in
survival analysis should theoretically increase the estima-
tion efficiency regarding the effects of treatment [11].
Although these methods have not generally been applied
to MS clinical trial data, Wang et al. [12] recently exam-
ined some of the models. Excellent reviews are available
regarding how these methods can contribute to the esti-
mation of treatment effects [11,13,14]. When using these
models, it is important to pay attention to the nature of
the models because the results of the estimation are
highly dependent on the clinical situation [15]. In real
clinical studies, the concerned events might occur rarely,
several events might occur simultaneously, or several
events might occur separately with high correlation.
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the relationship between the assumptions of the models
and the manner in which the events occur. For example,
if we analyse the disease data such that the deteriorations
of many lesions are found simultaneously, we should
select the model that can manage the count data
approach rather than the gap time modeling of event his-
tory analysis.
In this study, we focused on the extended Cox propor-
tional models and Poisson regression model using Gen-
eralized Estimating Equations (GEE), which can be
analyzed using existing statistical packages such as SAS.
Using these regression models, we can estimate the
adjusted treatment effect while considering the impor-
tant covariates that might affect the outcomes, whereas
the relapse rates provide only non-adjusted estimate
[16]. The objective of this study was to investigate the
performance of these models through a simulation study
with MS-specific data generation processes and to apply
various models that are used for estimating the treat-
ment effect to a real clinical trial data set. This data set
comprises the effect of IFN beta-1b on MS with special
attention to subjects with relapsing-remitting MS.
Methods
Subjects
A phase II randomized controlled clinical trial was con-
ducted to compare the effect o f2d i f f e r e n td o s e s( h i g h -
dose: 250 μga n dl o w - d o s e :5 0μg) of IFN beta-1b on
relapsing-remitting MS in Japan. Details of the trial
design, inclusion criteria, baseline demographics, and
efficacy results have been published [2]. In the trial, 205
patients with relapsing-remitting MS were randomized,
and efficacy was assessed in 188 patients (55 male and
133 female patients). The primary endpoint of the study
was the evaluation of the annual relapse rate. The per-
centage of patients who experienced a relapse more than
once during follow-up was 55.8% (53/95) of patients in
the high-dose group and 65.6% (61/93) of patients in the
low-dose group. In these groups, the maximum number
of relapses was 7, and the minimum,- 0, with a median of
1. The annual relapse rates in the high- and low-dose
groups as estimated by the person-time method were
0.763 and 1.069, respectively (relapse rate ratio = 0.714;
95% CI 0.560- 0.910; p = 0.006).
Models
Various survival models used for analysis of recurrent
event data and that handle clustered and multiple event
data have been proposed. Let lij(t)b et h eh a z a r df u n c -
tion of the jth recurrence of the ith subject at time t; l0
j(t) be the baseline hazard function of the jth recurrence
at time t; Yij(t) be the indicator variable for the jth
recurrence of the ith subject at time t, which is 1 when
the subject is at risk and under observation and 0 other-
wise; Xij(t)b et h ejth covariate vector of the ith subject
at time t;a n dbj be the parameter vector for the jth
recurrence, which includes the treatment effect. When
each recurrence is assumed to have common effect, we
omit the subscript j. Schematic forms of the models are
shown in Figure 1.
The first model to be considered is the ordinary time-
to-first-event model, which is formulated with the Cox
proportional hazard model (hereafter referred to as
“time-to-first-event Cox model”). It handles only the
time-to-first-event data and ignores the information of
the second or more events. Hereafter, the models that
can deal with this lack of information are shown.
Andersen and Gill [17] extended the Cox proportional
hazard model in the counting process formation (AG
model). A Poisson process in which, each counting pro-
cess has independent increments is assumed so that
multiple events within the same subjects are regarded
independently. The hazard of subject i at time t is
λi(t) = Yi(t)λ0(t)exp{Xi(t) β}.
Although subjects who have once experienced an
event are excluded from the risk set from that time in
the usual Cox model, subjects who have experienced at
least 1 event and are under observation can also be
included in the risk set in the AG model. Because the
baseline hazard is assumed to be common among sub-
jects, this model ignores the individual differences and
might be effective when the overall treatment effects are
of interest.
Prentice, Williams, and Peterson [18] also extended
the Cox model. They proposed the conditional model,
which assumes that a subject is not at risk for the jth
event until he/she has experienced the (j-1)th event,
where Yij(t) is 0 until the (j-1)th event and after which it
becomes 1 (PWP model). In terms of the time scale, 2
models are used. One model measures from the entry
time and is called the total time model (PWP-T model).
The hazard of the jth recurrence of subject i at time t is
λij(t)=Yij(t)λ0j(t)exp{Xi(t) βj}.
The other model resets the clock at every recurrence
and is called the gap time model (PWP-G model). Assign-
ing tj-1 a st h et i m ea tw h i c ht h e( j-1)th event occurs, the
hazard of the jth recurrence of subject i at time t is
λij(t)=Yij(t)λ0j(t − tj−1)exp{Xi(t) βj}.
Although the PWP model makes the interpretation easy,
the sizes of the risk sets become relatively small as the
number of events increases, making the estimates unstable.
Wei, Lin, and Weissfeld [19] modeled the marginal
distribution of the time of each occurrence of the event
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jth recurrence of subject i at time t is
λij(t)=Yij(t)λ0j(t)exp{Xi(t) βj}.
In this model, each recurrence is modeled as a sepa-
rate stratum, and each subject appears in all of the
strata so that no assumptions are made with respect to
the recurrence process. However, this may result in sub-
stantial efficiency loss because it ignores the obvious
dependency structure, in that the (j+1)th recurrent time
must exceed the jth.
On the other hand, Lee, Wei, and Amato [20] pro-
posed a model (LWA model) that assumes a common
baseline hazard, where the hazard can be written as
λij(t)=Yij(t)λ0(t)exp{Xi(t) βj}.
The same subjects can enter several risk sets simulta-
neously, although its unnaturalness is discussed at the
same time.
In terms of the inference of the parameter vector, the
use of robust variance, which can handle intra-subject
correlations, is considered to be desirable for all models
described above (AG, PWP, WLW, and LWA models).
Regarding the parameter estimation of the PWP, WLW,
and LWA models, each recurrence is assumed to have a
common effect in this study.
The Poisson regression model fits the framework of
the generalized linear models in which, the response
variable, which is the number of occurrences of the
event in a fixed time interval, follows Poisson distribu-
tion. Let μ(X) be the expected value of the number of
relapses; N(X), the total observation period; l(X), the
constant relapse rate of MS; X, the covariate vector; and
b, the parameter vector to be estimated. The relapse
rate can then be written as
log{λ(X)} =l o g

μ(X)
N(X)

= X β.
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Figure 1 Schematic forms of the various extended time-to-event Cox regression models. Each arrow represents a stratum. Arrow diagrams
describe about the behavior of ID = 1 in the sample data (DATA = MS) in Appendix (Additional file 1), who experiences the first event at day 51,
second event at day 185, third event at day 413 and finally have censored at day 692. (A) “Time-to-first-event Cox model” only uses the
information of the time to first event (the day 51). (B) “AG model” shows the renewal process of the events. (C) “PWP model” shows how the
conditional models are constructed. (D) “WLW model” and “LWA model” model the marginal distribution of each event occurrence time.
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The relapse rate is not necessarily constant through-
out the observation period; it is better to partition the
time axis into intervals of constant rates.
Consequently, the intra-subject correlation of the
relapse rate among the intervals can be discussed in
terms of GEE. GEE is an extension of generalized linear
models and regards a subject as a cluster so that the
treatment effect can be estimated considering the corre-
lation structure among response variables [21]. It is
expected to be a flexible method for analyzing recurrent
event data because it can be used even if many of the
aforementioned assumptions regarding the proportional
hazard models do not hold. In this study, the GEE-Pois-
s o nm o d e lw a sa p p l i e d ,a n di n t e r v a l sw e r es e ta t6
months, each with the common rate.
Simulation study
To determine which model is the most suitable for ana-
lyzing MS clinical trial data, we conducted the simula-
tion study with consideration of the disease progression
process or natural history. When performing a simula-
tion study, we should examine the event generation pro-
cess, which might be suited to the situation of the
disease progression process [22]. The data generation
process of this study was as follows. In a hypothetical
randomized controlled clinical trial with placebo (n =
100) and active (n = 100) groups, we assumed that each
patient had 10 hypothetical latent lesions in their brain
and that the lesions were in the inactive phase at the
entry time. The recurrence time was recorded after each
lesion developed to the active phase. This setting mod-
eled some MS pathological characteristics, such as time
and spatial distribution of the lesions. The total follow-
up period was set to 3 years, and the censoring time,
which was assumed to be independent from the recur-
rence time, was generated using a Weibull distribution
S(t)=e x p( - lt
g) with the shape parameter g = 2.1399
and the scale parameter l = 0.000000576. The time to
recurrence was also generated using a Weibull distribu-
tion, and 2 different scenarios were considered.
Scenario 1: All patients have individual identical Wei-
bull distribution parameters, g = 1.1452 and l =
0.00141.
Scenario 2: Mixture population of 3 different sets of
parameters; 46% of the population has g = 1.2442 and
l = 0.000604, 45% of the population has g =1 . 1 5 5 0a n d
l = 0.001578, and 9% of the population has g =1 . 9 6 9 4
and l = 0.0000661.
The parameters used in our simulation study were calcu-
lated from other clinical trial data in Japan [23], especially
for the placebo group, which can be regarded as the natural
history cohort [24]. The mixture proportions described in
Scenario 2 were obtained from the distribution of the
number of recurrences in the year preceding the study,
which was one of the important covariates. The hazard
ratio (relapse rate ratio) of the active group to the placebo
g r o u pw a ss e ta t1 / 1 . 3 ,s u c ht h et r u ev a l u eo ft h eC o x
regression parameter (log-hazard ratio) was log(1/1.3) =
-0.26236. Each simulation was repeated 1000 times, and
the results were evaluated via the bias and mean square
error (MSE). The bias is the difference between the esti-
mated and true (or reference) values; thus, the treatment
effect would be underestimated if we obtained positive bias
and, overestimated if we obtained negative bias. The MSE
considers both bias and variability as gauged by the var-
iance of parameter estimates.
After the simulation study, the models were applied to
the IFN beta real clinical trial data separately. All statis-
tical analyses, including the simulation study, were per-
formed using SAS version 9.1.3 (SAS Institute Inc.,
Cary, NC, USA). The SAS sample programs for the use
of these models are shown in the appendix of this article
(Additional file 1), and a dummy data set is used to clar-
ify the use of the models.
Results
The results of the simulation study are presented in
Table 1. AG, Poisson, and GEE-Poisson models showed
similar results, with positive bias and relatively small
MSE in both scenarios. Almost no bias was detected in
PWP-T, PWP-G, and LWA models in Scenario 1,
whereas they showed larger bias in Scenario 2. In the
WLW model, a relatively large bias with a negative
direction was noted, indicating that an overestimation of
the treatment effect and a large MSE were detected in
both scenarios.
The various aforementioned models were then applied
to the real clinical trial data introduced in the Methods
section with adjustment for some important covariates,
such as sex, age, EDSS score at entry time, total area of
MS lesions on the MRI scan at the entry time, and
number of recurrences in the year preceding the study.
Table 2 shows the results of the analysis. The hazard
ratio indicates the relative risk of the high-dose group to
Table 1 Bias and MSE from the simulation study
[Scenario 1] [Scenario 2]
Models Bias MSE Bias MSE
1: Time-to-first-event Cox regression -0.002 0.049 0.023 0.046
2: AG model 0.044 0.014 0.090 0.030
3-1: PWP-T model -0.001 0.018 0.080 0.022
3-2: PWP-G model 0.007 0.017 0.101 0.029
4: WLW model -0.162 0.076 -0.064 0.064
5: LWA model 0.001 0.017 0.046 0.037
6: Poisson regression model 0.044 0.016 0.090 0.026
7: GEE-Poisson model 0.046 0.014 0.088 0.030
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(WLW model) to 0.769 (time-to-first-event Cox model).
All models except the time-to-first-event Cox model
showed a significant effect of high-dose IFN beta-1b.
The standard error of the WLW model was the largest,
while the PWP-T and PWP-G models showed relatively
small values. The width of the confidence intervals of
the AG, PWP-T, PWP-G, WLW, LWA, Poisson, and
GEE-Poisson models was smaller than that of the time-
to-first-event Cox model.
Regarding the behavior of the other covariates besides
the IFN beta-1b variable, “the number of recurrences in
the year preceding the study” showed significant differ-
ences in all 8 models. As the number increased, the
hazard of recurrence in the study increased (range of
hazard ratio among the 8 models: 1.164-1.375).
Discussion
Because MS is a heterogeneous disease with a variety of
subtypes and transitional cases, it is not easy to evaluate
drug efficacy. By conducting a simulation study and
applying it to real clinical trial data, we examined var-
ious extended Cox regression models and a Poisson
regression model using GEE, which can handle recur-
rent events - not only the number of recurrences or the
time to the first event, but all recurrences that occurred
during the follow-up period. With the use of the
extended models, significant effects were detected and
the importance of utilizing more than 1 recurrent time
was suggested by our analyses.
From the simulation study results, treatment effect was
relatively overestimated in the WLW model. The same
tendency was observed in the analysis of the real data; the
WLW model showed the smallest hazard ratio. This over-
estimation tendency might not be desirable, especially in
confirmatory trials. The bias and MSE of the LWA model
in Scenario 1 were small for homogeneous population
because of the similarity of the assumption of the data
generation process; however, in Scenario 2, both bias and
MSE became larger to some extent for heterogeneous
population. In terms of MSE of the PWP-T and PWP-G
models, totally preferable results were obtained, but the
bias differences between Scenarios 1 and 2 for each model
were approximately 2 times larger than those of the other
models; this finding suggests of possible unstable features
in the PWP models. For the time-to-first-event Cox
model, AG model, Poisson regression model, and GEE-
Poisson model, no extreme differences were found.
We are then left to select the best model for our data.
All models have their own assumptions and characteris-
tics, and so, our decision must consider the nature and
system of disease progression that we have analyzed in
advance in order to make the correct choice. When we
consider the pathological condition in MS, such as the
time and spatial distribution of latent lesions, the LWA
model seems to be reasonable because of the assumption
of a common baseline hazard, which means that each
latent lesion has the same risk of development. If we can
assume that all subjects have the same number of lesions
that can develop at the same risk, the LWA model
becomes conceivable. In the same way, if we can assume
that all subjects have the same number of lesions that
can develop at different risks, the WLW model seems to
be best fitted. However, such settings would be unrealis-
tic. In addition, the precision of the estimates in the
WLW and LWA models is relatively poor. As the num-
ber of lesions increases, the number of strata also
increases, which might lead to unstable estimates.
If we assume that the independent increments for all
events are even among subjects, then the AG model is
reasonable; however, this assumption would be unna-
tural in this case. PWP models would involve a similar
situation despite small standard errors. In fact, the mar-
tingale residuals, which enabled us to examine the incre-
ment dependency, showed negative slopes throughout
the period. This suggests that the assumptions that the
AG and PWP models required would not exactly hold.
The estimates of the Poisson regression and GEE-Pois-
son models were quite similar, so the advantage of using
the GEE-Poisson model was not entirely clear in our
study. However, if we had had a longer follow-up period
and more time intervals, the method that accounts for
the intra-subject correlation structure among intervals
would be the more attractive model.
Table 2 Estimates of treatment effects for MS clinical trials in Japan
Models Parameter Estimates Standard Error Hazard Ratio [95%CI] P value
1: Time-to-first-event Cox regression -0.263 0.194 0.769 [0.526, 1.123] 0.174
2: AG model -0.377 0.170 0.686 [0.492, 0.957] 0.027
3-1: PWP-T model -0.268 0.132 0.765 [0.591, 0.989] 0.041
3-2: PWP-G model -0.306 0.135 0.736 [0.565, 0.960] 0.024
4: WLW model -0.489 0.231 0.613 [0.390, 0.965] 0.035
5: LWA model -0.427 0.195 0.653 [0.445, 0.957] 0.029
6: Poisson regression model -0.371 0.171 0.690 [0.493, 0.965] 0.030
7: GEE-Poisson model -0.352 0.169 0.703 [0.505, 0.980] 0.037
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extended Cox regression models (AG, PWP, WLW, and
LWA models) would be difficult to be completely exam-
ined because of the uncertainty of MS pathological and/
or clinical deterioration mechanisms and that fact that
no one can prove the correctness of these assumptions.
The Poisson regression and GEE-Poisson models are
free of such assumptions. Moreover, in terms of the
advanced nature regarding consideration of intra-subject
correlation for recurrences in the GEE-Poisson model,
the GEE-Poisson model is preferred over the Poisson
regression model. However, further study regarding the
behavioral characterization among these models is still
needed.
Conclusions
Our results indicate that the use of alternative models
that include recurrence event data, especially the GEE-
Poisson model, may provide better analysis for estimat-
ing the treatment effect.
Additional material
Additional file 1: Appendix: SAS programming codes (example). The
SAS sample programs for the use of the regression models shown in this
study are provided using a dummy data set.
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